REACTION SCHEME 2



Formula 1 (5)

FIG. 1

REACTION SCHEME 3



Where FM represents 9-fluorenyl., and m is an integer of 1-20

FIG. 2

REACTION SCHEME 4



Formula 1

Where X is a linker of formula:
$-NH-(CH_2)_m\ NHC(O)(CH_2)_nC(O)NH(CH_2)_m\ -NH-$
in which m and n are independently integers of 1-20

FIG. 3

REACTION SCHEME 5



(9)



(10)



(11)

in which m is an integer of 1-20, and FM is 9-fluorenyl

FIG. 4

REACTION SCHEME 6



Formula 1

where R is a protecting group, such as an ester, m and n are as defined above, and FM is 9-fluorenyl

FIG. 5

REACTION SCHEME 7



FIG. 6

REACTION SCHEME 8



Formula 1

FIG. 7

REACTION SCHEME 9



FIG. 8



FIG. 9

REACTION SCHEME 11



Formula 1

FIG. 10

REACTION SCHEME 12



Formula 1

FIG. 11

FIG. 12

Examples of dimeric display



FIG. 13

Examples of trimeric display



FIG. 14

Examples of tetrameric display



FIG. 15

Examples of higher order polyvalent display



FIG. 16

C3 SUBSTITUENT



SUMATRIPTAN



ZOLMITRIPTAN

C5 SUBSTITUENT



SUMATRIPTAN



ZOLMITRIPTAN

FIG. 17

SUMATRIPTAN BUILDING BLOCKS

C3PharmacophoricBuilding Blocks





C5PharmacophoricBuilding Blocks





Pharmacophoric Building Blocks that contain a Spacer





FIG. 18

MULTIVALOMERS OF SUMATRIPTAN

1 The Indole Core



2 C3 Substituent



3. C5 Substituent



C3 ELECTROPHILE TO PROVIDE MULTIVALOMERS





C3 NUCLEOPHILE TO PROVIDE MULTIVALOMERS



$X = -CH_2Br$	(a)DCM, pyrdine	
$X = -CHO$	(a)DCM, $NaBH(OAc)_3$, AcOH	
$X = -CO_2H$	(a)DIC, DIPEA, DMF	

FIG. 19

C5 FUNCTIONALIZATION OF SUMATRIPTAN

Electrophilic Pharmacophoric Monovalomer



(a)DMF < DIPEA < RT



Nucleophilic Pharmacophoric Monovalomer



X = $-CH_2Br$



FIG. 20


SUMATRIPTAN SPECIFICS
C3 Multivalomers
CHO
OHC
(a)
(a)NaBH(OAc)3, AcOH, CHCl3
OMs
HN
NH
(a)
(a) CHCl3, pyridine
C5 Multivalomers
Br
Br
(a) NaH, DMF, RX
H2N
NH2
(a)
(a)DMF < DIPEA < RT
PhO

FIG. 21


SUMATRIPTAN SPACERS
C3 Acid Spacer
OH
N
O
H
N
S
O
O
N
H
H2N
NH2
(a)
(a) DMF, DIPEA, DIC ,RT
C5 Acid Spacer
CO2Et
NH
(a)
(a) DIC, DIPEA, DMF
R
HN

FIG. 22


Introduction of Spacer To Faciliate Multivalomer Formation
C3 Sumatriptan Series
(a)
(b)
R = Et
R = H
(c)
C5 Sumatriptan Series
(a)
(b)
R = Et
R = H
(a)
(a) DIPEA, DCM, BrCH2CO2Et (b) LiOH, THF, H2O, (c) DIC, DIPEA, DMF

FIG. 23

MUSCARINIC ANTAGONISTS USED IN AIRWAY DISEASE

I) Airway disease



IPRATROPIUM BROMIDE



OXITROPIUM BROMIDE



REVATROPATE



TIOTROPIUM BROMIDE

FIG. 24

SITES FOR DIMERIZATION

Nitrogen Atom of Tropane Core



Aromatic Ring



Primary Hydroxyl



Suitable Pharmacophoric Building Blocks

Nitrogen Atom of Tropane Core
Acid Series





Amine Series





FIG. 25

Ipratropium Multivalomers 1– Different points of Attachment



n defines the valency of the multivalomer

◯ defines the framework core

⟶ distinguishes the differing points of attachment of ipratropium



FIG. 26

Ipratropium Multivalomers 2-Alternative Framework Cores



FIG. 27


Ipratropium Multivalomers 3-Alternative Framework Valency
n
Br⁻
HO
H
O
O
2
3
4
Dimeric Series
Trimeric Series
Tetrameric Series

FIG. 28

Ipratropium Multivalomers 4–Relative Pharmacophore Orientation



FIG. 29


IPRATROPIUM 1–N–Linked Multivalomers
1. Alkylation/Quaternization
CBZ
Br
N
Br
4
(a)
(b)
(c)
1
2
3
5
6
Br⁻
CBZ
BnO
OBn
HO
OH
(a) DIC, DMAP, DMF (b) CHCl3 (c) Pd/C, H2,EtOAc

FIG. 30

IPRATROPIUM 2-N-Linked Multivalomers

1. Reductive Amination/Quaternization



(a)DIC,DMF,DMF (b)Pd/C,H_2,EtOAC (c)$NaBH(OAc)_3$,$CHCl_3$,AcOH
(d)MeBr,$CHCl_3$(e)TBAF, THF

FIG. 31

IPRATROPIUM 3–O–Linked Multivalomers



(a)NaH, THF (b)MeBr, $CHCl_3$, REFLUX

FIG. 32



(a)NaH,DME,heat (b)Pd/C,H_2,EtOAc (c)NaH,DME,heat (d)MeBr,$CHCl_3$,heat

FIG. 33

AT1 RECEPTOR ANTAGONISTS



LOSARTAN (Cozaar)
(Dupont Merck)



VALSARTAN (Diovan)
(Novartis)

FIG. 34



IRBESARTAN
(Sanofi)



CANDESARTAN (Atacand)
(Takeda)



EPROSARTAN (Teveten)
(Smith KlineBeecham)



TASOSARTAN (Verdia)
(Wyerth-Ayerst)

FIG. 35



TELMISARTAN
(Boehringer Ingelhiem)
Phase III



RIPISARTAN
(Bristol Myers Squibb)
Phase II

Phase II
CS-866 Sankyo
DA-727 Daiichi
KRH-594 Wakunga
LR-B/081 Lusofarmaco
TAK-536 Takeda
YM-358 Yamanouchi

FIG. 36

FIG. 37

Losartan Multivalomers 1–Differing Points of Attachment

1. Aryl Linked Multivalomers



2. Butyl Linked Multivalomers



FIG. 38

Losartan Multivalomers 1–Differing Points of Attachment

1. Tetrazole Linked Multivalomers



2. Aryl Linked Multivalomers



FIG. 39

Lorsartan Multivalomers 2-Differing Valency of Multivalomer



FIG. 40


Lorsartan Multivalomers 3-Differing Framework Building Blocks
Cl
HO
N
N
N=N
N
N
2
2
1. Alkyl Series
2. Aromatic Series
O
3 H-bond donor
H
N
4 H bond acceptor
O
N
N
O
5 Basic
N
N
N
6 Acidic
CO2H
CO2H

FIG. 41

Losartan Multivalomers 4-Different Relative Connectivity



FIG. 42

Losartan Multivalomers 5-Heterovalomers



LOSARTAN (Cozaar)



VALSARTAN (Diovan)

Heterovalomers



Losartan/Valsartan

FIG. 43

Losartan Multivalomers Synthesis 1-Hydroxyl Linked Multivalomer



(a)NaH, DMF (b)nBu_4NF, THF (c)NaH, DMF, $BrCH_2C_6H_4CH_2Br$ (d)HCl, MeOH.

FIG. 44

Losartan Multivalomer Synthesis 2-Hydroxyl Linked Multivalomer



(a)NaOMe,MeOH,DMF (b)NaH,DMF (c)Bu_3SnN_3,xylene,reflux

FIG. 45

Losartan Multivalomer Synthesis 3–Tetrazole Linked Multivalomers

Strategy–Selective tetrazole alkylation in the presence of the primary hydroxyl



(a)Bu_3SnN_3, xylene, 24hr reflux (b)NaOH, THF

For precedent see Carini, D. J., J. Med. Chem., 1991, 34, 2525–2547

FIG. 46

β_2 Adrenergic Drugs

1. Rapid Onset Inhaled Drugs



Albuterol
(Glaxo Wellcome)



Terbutaline

2. Prolonged Duration of Action Inhaled Drugs



Salmeterol
(Glaxo Wellcome)



Formoterol
(Novartis)

Notes–1 These drugs are racemates.
Multivalomers will produce diastereomers

FIG. 47

Albuterol Multivalomers

1. N atom

2. Ethanolamine function

3 Phenyl Ring

New substitution



Phenolic Group



Benzyl Alcohol



M represents a site for the attachment of the monovalomer to the framework core.

FIG. 48

1 Valency of Framework Building Block



Dimeric Ligand



Trimeric Ligands

2. Relative Orientation of Monovalomer Building Blocks



3 Mixed Multivalomers Derived from Different β_2-agonists



Albuterol/Formeterol

Albuterol/Clenbuterol

FIG. 49


Albuterol Multivalomers 1–Different Points of Attachment
n
n
n
n defines the valency of the multivalomer
defines the framework core
distinguishes the differing points of attachment of albuterol
Generic Examples
Specific Example
Series 1
Series 2
NH
HN
OH
HO
O
2

FIG. 50A

FIG. 50B


Albuterol Multivalomers 2-Alternative Framework Cores
OH
H
N
HO
HO
n
n
2
1. Alkyl series
2. Aromatic Series
O
3 H-bond donor
H
N
4. H bond acceptor
O
N
N
O
5. Basic
N
N
N
6 Acidic
CO2H
CO2H

FIG. 51

Albuterol Multivalomers 3–Alternative Framework Valency



FIG. 52


Albuterol Multivalomers 4–Relative Pharmacophore Orientation
Pharmacophore Orientation
Albuterol

FIG. 53

Albuterol Multivalomers 5–Mixed β_2 Adrenergic Heterovalomers

Heterovalomers



FIG. 54



reagents and conditions:
i) HOBt, PyBOP, DIPEA, DMF, rt, 24h;
ii) $LiAlH_4$, THF, 0°C to 80°C;
iii) H_2(1 atm), 10% Pd/C, EtOH, rt, 24h

FIG. 55



reagents and conditions:
i) HOBt, PyBOP, DIPEA, DMF, rt, 24h;
ii) $LiAlH_4$, THF, 0°C to 80°C;
iii) H_2(1 atm), 10% Pd/C, EtOH, rt, 24h.

FIG. 56



reagents and conditions:
i) 1,6-hexanedioic acid, DIPEA, HOBT, PyBOP, DMF, rt,
ii) TFA/CH_2Cl_2, 0°C.

FIG. 57



reagents and conditions:
i) terphathalic acid, DIPEA, HOBT, PyBOP, DMF, rt:
ii) TFA/CH_2Cl_2, 0°C:
iii) $LiAlH_4$, THF, 80°C;

FIG. 58